论文部分内容阅读
将药物植入于人体组织间质或皮下,直接在肿瘤细胞外组织液中缓慢释放、长期发挥作用的化疗方法称之为缓释化疗。恶性肿瘤在原发肿瘤切除术后,可促使原先处于休眠状态的微转移瘤生长加速,造成残存肿瘤组织生长能力增强,且由于术后血供的改变,可降低肿瘤区域的化疗药物浓度。因此,手术后的腹腔是癌细胞种植生长的适宜土壤,但同时又是残留微小癌灶化疗的敏感期。根据临床研究证据及国内外循证医学证据证明,术中植入区域性缓释化疗剂是消灭残留癌小病灶,降低复发率的最佳时机。现将缓释化疗的研究及临床应用进展综述如下。
The drug is implanted in human tissue interstitial or subcutaneous, directly in the extracellular tissue fluid in the tumor slowly release, long-term effect of chemotherapy known as sustained-release chemotherapy. Malignant tumors in the primary tumor resection, can promote the growth of the original dormant micrometastases growth, resulting in increased ability of residual tumor growth, and because of postoperative blood supply changes, can reduce the concentration of chemotherapy in the tumor area. Therefore, the peritoneal cavity after surgery is a suitable soil for the growth of cancer cells, but it is also the sensitive period for residual micro-cancer chemotherapy. According to clinical research evidence and evidence-based evidence at home and abroad evidence that intraoperative implantation of regional sustained release chemotherapeutic agents is to eliminate small residual cancer and reduce the recurrence rate of the best time. Now the study of slow release chemotherapy and clinical application of progress are summarized below.